StockData

Camp4 Therapeutics vs Dianthus Therapeutics

CAMP and DNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAMP and DNTH compare

Dianthus Therapeutics is the larger company, worth 19 times as much as Camp4 Therapeutics ($5.0B against $264M).

Dianthus Therapeutics scores higher on the StockData Score (7 against 6 for Camp4 Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAMPDNTH
Size and price
Market cap$264M$5.0B
Share price$4.20$89.30
Change, 1 year0.96%144%
Change, 5 years−98.2%−16.6%
Beta (5Y)2.741.44
Employees4892
StockData Score
Total score67 (better)
Valuation score00
Growth score1 (better)0
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S49.5×–
P/B2.5× (better)4.0×
FCF yield−10.0%–
Fair value$2.59–
Margin of safety−62.3%–
Growth
Revenue growth (TTM)39.9%–
Profitability
Operating margin−1001%–
Net margin−2276%–
FCF margin−496%–
Return on equity−146%−22.6% (better)
Return on invested capital–−22.2%
Financial health
Debt / equity0.000.00
Current ratio6.4230.02 (better)
Altman Z-score1.6785.71 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Dividend yield0.00%0.00%
Years of dividend growth00
Buyback yield–−0.01%
Shareholder yield0.00% (better)−0.01%
Ownership
Held by institutions66.5%118%
Held by insiders21.7%9.1%
Insider net buying, 12 months−$2.4M (better)−$63.8M
Short interest, % of float6.6%18.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.